IgG Antibody

Overview

Immunoglobulin gamma (IgG) is the most common class of antibody in blood and extracellular fluid. Approximately 75% of serum antibodies in humans are IgG. There are four immunoglobulin gamma subclasses: one, two, three and four. IgG1 is the most common, with 68% of all gamma class antibodies being G1, and G4 is the least common at 4%. Gamma class antibodies are found primarily in the secondary immune response, class switching from IgM and IgD. They are the only class of antibody that can cross the placenta, and along with IgA secreted in breast milk, provide the neonate with humoral immunity before immune system development occurs.

This antibody recognizes a protein of 75kDa identified as the gamma heavy chain of human immunoglobulins. It does not cross-react with alpha, mu, epsilon, or delta heavy chains, T-cells, monocytes, granulocytes, or erythrocytes. The IgG antibody is useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. The most common feature of these malignancies is the restricted expression of a single heavy chain class. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is clonal and therefore malignant.

This anti-IgG antibody is supplied as CF488 Conjugate (Mouse, Monoclonal (mouse origin), clone IG266, Mouse IgG2a, kappa, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.

Key elements and design rationale

• Target: IgG
• Format: CF488 Conjugate
• Localization: Cytoplasm, Cell Surface and Secreted
• Species reactivity: Human
• Applications (listed): FACS, IF, IHC-P
• Conjugate: Unconjugated
• Clone and antibody class: Monoclonal (mouse origin), clone IG266, Mouse IgG2a, kappa

Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.

Biological background

IgG is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.

Research relevance and current trends

• Profiling IgG expression across model systems, perturbations, and time points to support mechanistic hypotheses.
• Combining antibody-based detection with multi-omics or imaging readouts to link IgG signal with phenotype.
• Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.

Common research applications

• FACS
• IF
• IHC-P

Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.

Notes for experimental interpretation

• Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
• Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
• Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.